News of Note

Article

From the current literature

Beard C, Stason W, Wang Q, et al: Effects of complementary therapies on clinical outcomes in patients being treated with radiation therapy for prostate cancer. Cancer 117(1):96–102, 2011.

Bookbinder M, Glajchen M, McHugh M, et al: Nurse practitioner-based models of specialist palliative care at home: Sustainability and evaluation of feasibility. J Pain Symptom Manage 41(1):25–34, 2011.

Davies A, Sitte T, Elsner F, et al: Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate release morphine sulfate in breakthrough cancer pain. J Pain Symptom Manage 41(2):358–366, 2011.

Field J, Hazinski M, Sayre M: Part I: Executive summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 122(18 Suppl 3):S640–S656, 2010.

Fredericks A, Hollis G, Stricker C: Diagnosis and management of opioid-induced bowel dysfunction in patients with advanced cancer. Clin J Oncol Nurs 14(6):701–704, 2011.

Irwin M, Klemp J, Glennon C, et al: Oncology nurses’ perspectives on the state of cancer survivorship care: Current practices and barriers to implementation. Oncol Nurs Forum 38(1):E11–E19, 2011.

Kim Y, Kashy D, Spillers R, et al: Needs assessment of family caregivers of cancer survivors: Th ree cohorts comparison. Psychooncology 19(6):573–582, 2010.

Kris M, Benowitz S, Adams S, et al: Clinical cancer advances 2010: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol 28(36):5327–5347, 2010.

Ledermann J, Kristeleit RS: Optimal treatment for relapsing ovarian cancer. Ann Oncol 21(Suppl 7):vii218–vii222, 2010.

Masi G, Vasile E, Loupakis F, et al: Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: An update analysis. J Natl Cancer Inst 103(1):21–30, 2011.

Mehnert A: Employment and work-related issues in cancer survivorship. Crit Rev Oncol Hematol 77(2):109–130, 2011.

Mitchell A, Chan M, Bhatti H, et al: Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: A meta-analysis of 94 interview-based studies. Lancet Oncol 12(2):160–174, 2011.

Morgan C, Tillett T, Braybrooke J, et al: Management of uncommon chemotherapy-induced emergencies. Lancet Oncol January 26, 2011. Epub ahead of print.

Palos G, Mendoza T, Liao K, et al: Caregiver symptom burden: The risk of caring for an underserved patient with advanced cancer. Cancer 117(5):1070–1079, 2011.

Porter L, Keefe F, Garst J, et al: Caregiver-assisted coping skills training for lung cancer: Results of a randomized clinical trial. J Pain Symptom Manage 41(1):1–13, 2011.

Rayner L, Price A, Hotopf M, et al: The development of evidence-based European guidelines on the management of depression in palliative cancer care. Eur J Cancer 47(5):702–712, 2011.

Taylor S, Harley C, Campbell L, et al: Discussion of emotional and social impact of cancer during outpatient oncology consultations. Psychooncology 20(3):242–251, 2011.

Turaga K, Malafa M, Jacobsen P, et al: Suicide in patients with pancreatic cancer. Cancer 117(3):642–647, 2011.

van Ryn M, Sanders S, Kahn K, et al: Objective burden, resources and other stressors among informal cancer caregivers: A hidden quality issue? Psychooncology 20(1):44–52, 2011.

Wood J, Chapman K, Eilers J: Tools for assessing nausea, vomiting and retching: A literature review. Cancer Nurs 34(1):E14–E24, 2011.

Recent Videos
Oncologists are still working on management strategies for neuropathy; a common adverse effect related to chemotherapeutics for ovarian cancer.
Genetic testing information can be used to risk-stratify ovarian cancer survivors for breast cancer, particularly those with BRCA1 or BRCA2 mutations.
Genetic testing for ovarian cancer may help inform treatment decisions for patients with advanced disease, particularly regarding PARP inhibitor use.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Patients who respond to avutometinib/defactinib may be maintained on treatment for long periods of time, says Rachel N. Grisham, MD.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Related Content